Protagonist Therapeutics, Inc Payments to Acquire Debt Securities, Available-for-sale
Protagonist Therapeutics, Inc (PTGX) reported Payments to Acquire Debt Securities, Available-for-sale of $203.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-05
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $134.68M, a 100.55% increase year-over-year.
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $68.97M, a 67.78% decline year-over-year.
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $104.27M, a 8.86% decline year-over-year.
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $161.12M, a 39.58% decline year-over-year.
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for fiscal 2025 was $546.59M, a 12.08% decline from fiscal 2024.
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for fiscal 2024 was $621.70M, a 225.42% increase from fiscal 2023.
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for fiscal 2023 was $191.04M, a 11.09% decline from fiscal 2022.
- Protagonist Therapeutics, Inc payments to acquire debt securities, available-for-sale for fiscal 2022 was $214.87M, a 25.02% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $134.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $203.64M 10-Q · filed 2026-08-05 | $307.92M derived: sum of 3 quarters · filed 2026-08-05 | $469.04M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $68.97M 10-Q · filed 2026-05-05 | $173.24M derived: sum of 2 quarters · filed 2026-05-05 | $334.36M derived: sum of 3 quarters · filed 2026-05-05 | $401.51M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $104.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $265.39M derived: sum of 2 quarters · filed 2026-02-25 | $332.55M derived: sum of 3 quarters · filed 2026-08-05 | $546.59M 10-K · filed 2026-02-25 |
| 2025-09-30 | $161.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $228.27M derived: sum of 2 quarters · filed 2026-08-05 | $442.31M 10-Q · filed 2025-11-06 | $556.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $67.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $281.19M 10-Q · filed 2026-08-05 | $395.60M derived: sum of 3 quarters · filed 2026-08-05 | $662.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $214.04M 10-Q · filed 2026-05-05 | $328.45M derived: sum of 2 quarters · filed 2026-05-05 | $595.12M derived: sum of 3 quarters · filed 2026-05-05 | $770.07M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $114.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $381.07M derived: sum of 2 quarters · filed 2026-02-25 | $556.03M derived: sum of 3 quarters · filed 2026-02-25 | $621.70M 10-K · filed 2026-02-25 |
| 2024-09-30 | $266.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $441.62M derived: sum of 2 quarters · filed 2025-11-06 | $507.29M 10-Q · filed 2025-11-06 | $605.26M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $174.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $240.63M 10-Q · filed 2025-08-06 | $338.60M derived: sum of 3 quarters · filed 2026-02-25 | $397.55M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $65.67M 10-Q · filed 2025-05-06 | $163.64M derived: sum of 2 quarters · filed 2026-02-25 | $222.59M derived: sum of 3 quarters · filed 2026-02-25 | $228.66M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $97.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $156.92M derived: sum of 2 quarters · filed 2026-02-25 | $162.99M derived: sum of 3 quarters · filed 2026-02-25 | $191.04M 10-K · filed 2026-02-25 |
| 2023-09-30 | $58.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $65.02M derived: sum of 2 quarters · filed 2024-11-07 | $93.08M 10-Q · filed 2024-11-07 | $173.67M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $6.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $34.12M 10-Q · filed 2024-08-06 | $114.72M derived: sum of 3 quarters · filed 2025-02-21 | $146.88M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $28.06M 10-Q · filed 2024-05-07 | $108.66M derived: sum of 2 quarters · filed 2025-02-21 | $140.81M derived: sum of 3 quarters · filed 2025-02-21 | $187.10M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $80.59M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $112.75M derived: sum of 2 quarters · filed 2025-02-21 | $159.04M derived: sum of 3 quarters · filed 2025-02-21 | $214.87M 10-K · filed 2025-02-21 |
| 2022-09-30 | $32.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $78.45M derived: sum of 2 quarters · filed 2023-11-02 | $134.28M 10-Q · filed 2023-11-02 | $164.97M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $46.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $102.12M 10-Q · filed 2023-08-03 | $132.81M derived: sum of 3 quarters · filed 2024-02-27 | $225.25M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $55.83M 10-Q · filed 2023-05-04 | $86.52M derived: sum of 2 quarters · filed 2024-02-27 | $178.96M derived: sum of 3 quarters · filed 2024-02-27 | $255.22M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $30.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $123.13M derived: sum of 2 quarters · filed 2024-02-27 | $199.38M derived: sum of 3 quarters · filed 2024-02-27 | $286.59M 10-K · filed 2024-02-27 |
| 2021-09-30 | $92.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $168.70M derived: sum of 2 quarters · filed 2022-11-08 | $255.90M 10-Q · filed 2022-11-08 | $388.33M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $76.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $163.46M 10-Q · filed 2022-08-04 | $295.89M derived: sum of 3 quarters · filed 2023-03-15 | $376.73M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $87.20M 10-Q · filed 2022-05-05 | $219.63M derived: sum of 2 quarters · filed 2023-03-15 | $300.48M derived: sum of 3 quarters · filed 2023-03-15 | $346.35M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $132.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $213.27M derived: sum of 2 quarters · filed 2023-03-15 | $259.14M derived: sum of 3 quarters · filed 2023-03-15 | $280.03M 10-K · filed 2023-03-15 |
| 2020-09-30 | $80.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $126.72M derived: sum of 2 quarters · filed 2021-11-03 | $147.60M 10-Q · filed 2021-11-03 | $196.73M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $45.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $66.75M 10-Q · filed 2021-08-04 | $115.88M derived: sum of 3 quarters · filed 2022-02-28 | $181.23M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $20.88M 10-Q · filed 2021-05-04 | $70.01M derived: sum of 2 quarters · filed 2022-02-28 | $135.36M derived: sum of 3 quarters · filed 2022-02-28 | $166.09M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $49.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $114.48M derived: sum of 2 quarters · filed 2022-02-28 | $145.21M derived: sum of 3 quarters · filed 2022-02-28 | $166.94M 10-K · filed 2022-02-28 |
| 2019-09-30 | $65.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $96.08M derived: sum of 2 quarters · filed 2020-11-04 | $117.81M 10-Q · filed 2020-11-04 | $136.92M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | $30.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $52.46M 10-Q · filed 2020-08-06 | $71.57M derived: sum of 3 quarters · filed 2021-03-10 | $84.51M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | $21.73M 10-Q · filed 2020-05-07 | $40.84M derived: sum of 2 quarters · filed 2021-03-10 | $53.77M derived: sum of 3 quarters · filed 2021-03-10 | |
| 2018-12-31 | $19.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $32.05M derived: sum of 2 quarters · filed 2021-03-10 | $71.06M 10-K · filed 2021-03-10 | |
| 2018-09-30 | $12.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $51.95M 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | $39.01M 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $39.55M 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |